What is the step-wise approach to managing status epilepticus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Step-wise Management of Status Epilepticus

The management of status epilepticus requires immediate intervention following a structured protocol, with benzodiazepines as first-line treatment followed by antiseizure medications and, if necessary, anesthetic agents for refractory cases. 1

Initial Assessment and Stabilization (0-5 minutes)

  • Assess circulation, airway, and breathing (CAB)
  • Position patient on their side (recovery position)
  • Clear area of hazardous objects
  • Provide airway protection interventions
  • Administer high-flow oxygen
  • Check blood glucose level
  • Establish IV access
  • Monitor vital signs

First-Line Treatment (5-20 minutes)

For Convulsive Status Epilepticus:

  • Lorazepam 0.1 mg/kg IV (maximum 4 mg) 1
    • May repeat once after 5 minutes if seizures persist
    • Maximum of 2 doses
    • Monitor for respiratory depression, especially when combined with other CNS depressants 2

For Non-convulsive Status Epilepticus:

  • Lorazepam 0.05 mg/kg IV (maximum 1 mg) 3
    • May repeat every 5 minutes up to 4 doses to control electrographical seizures

Second-Line Treatment (20-40 minutes)

If seizures persist after adequate benzodiazepine administration:

  • Levetiracetam 40 mg/kg IV (maximum 2,500 mg) as a bolus 3, 1
    • Preferred for young females, patients with renal or hepatic impairment, and those on multiple medications due to minimal drug interactions and favorable side effect profile

OR

  • Valproate 20-30 mg/kg IV (88% efficacy rate)
    • Avoid in young females due to teratogenicity risk 1

OR

  • Phenytoin/Fosphenytoin 18-20 mg/kg IV (56% efficacy rate)
    • Monitor for hypotension, cardiac dysrhythmias, and purple glove syndrome 1

Third-Line Treatment (40-60 minutes)

If seizures continue after second-line therapy:

  • Transfer to intensive care unit (ICU)
  • Add Phenobarbital 10-20 mg/kg IV (maximum 1,000 mg) 3, 4
  • Initiate continuous EEG monitoring
  • Consider corticosteroids if indicated (particularly for autoimmune causes) 3

Refractory Status Epilepticus (>60 minutes)

If seizures persist despite above measures:

  • Midazolam continuous infusion (loading dose 0.2 mg/kg, followed by 0.1-0.4 mg/kg/hour) 4

OR

  • Propofol continuous infusion (loading dose 1-2 mg/kg, followed by 2-10 mg/kg/hour) 4

Super-Refractory Status Epilepticus (>24 hours)

If seizures continue or recur 24 hours after anesthetic therapy:

  • Ketamine infusion
  • Barbiturates (pentobarbital or thiopental)
  • Consider additional non-sedating antiseizure medications
  • Evaluate for underlying causes requiring specific treatment (particularly autoimmune encephalitis) 4

Maintenance Therapy After Resolution

  • Lorazepam 0.05 mg/kg (maximum 1 mg) IV every 8 hours for 3 doses 3
  • Levetiracetam 15-30 mg/kg IV every 12 hours 3
  • Phenobarbital 1-3 mg/kg IV every 12 hours if used during acute management 3

Monitoring

  • Continuous EEG monitoring for refractory and super-refractory cases
  • Regular vital sign monitoring
  • Assess for respiratory depression, especially with benzodiazepines and barbiturates
  • Monitor for hypotension with phenytoin/fosphenytoin and anesthetic agents
  • Evaluate for drug-specific adverse effects

Prognosis and Outcomes

Status epilepticus carries significant mortality risk, ranging from 5-22% overall 3. Mortality increases with:

  • Increasing age
  • Underlying etiology (particularly CNS infections)
  • Medical comorbidities
  • Treatment refractoriness (10% mortality in responsive cases, 25% in refractory, and nearly 40% in super-refractory SE) 4

Important Considerations

  • Time is critical - delays in treatment increase mortality and neurological sequelae
  • Adequate dosing of first-line agents is essential for successful seizure termination
  • Always investigate and treat underlying causes (metabolic derangements, infections, stroke, trauma)
  • Institutional protocols improve outcomes by standardizing care and reducing treatment delays 5
  • Continuous EEG monitoring is essential for non-convulsive status epilepticus and after control of convulsive status epilepticus 5

References

Guideline

Seizure Management in Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Status epilepticus in the ICU.

Intensive care medicine, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.